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Abstract: Cardiac ischemia/reperfusion (I/R) injury occurs in several important clinical contexts including percutaneous 
coronary interventions for acute myocardial ischemia, cardiac surgery in the setting of cardiopulmonary bypass, and 
cardiac transplantation. While the pathogenesis of I/R injury in these settings is multifactorial, it is clear that activation of 
the innate immune system and the resultant inflammatory response are important components of I/R injury. Toll-like 
receptor 4 (TLR4), originally identified as the sensor for bacterial lipopolysaccharide (LPS), has also been shown to serve 
as a sensor for endogenous molecules released from damaged or ischemic tissues. Accordingly, recent findings have 
demonstrated that TLR4 not only plays a central role as a mediator of cardiac dysfunction in sepsis, but also serves as a 
key mediator of myocardial injury and inflammation in the setting of I/R. Furthermore, TLR4 may play a role in the 
development of atherosclerotic lesions. Other studies have implicated TLR4 in the adverse remodeling that may occur 
after ischemic myocardial injury. This emerging body of literature, which is reviewed here, has provided new insight into 
the early molecular events that mediate myocardial injury and dysfunction in the setting of I/R injury. 
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TOLL-LIKE RECEPTORS (TLRS) 
  TLRs are a family of evolutionarily conserved receptors 
that play a critical role in activation of the innate immune 
system in response to microbial invaders. In 1996, Lamaitre 
and colleagues first reported that a Drosophila protein 
known as Toll, which was known to play a role in the 
development of the fly, was also an important mediator of 
the host immune response against fungal infection in the 
adult fly [1]. Medzhitov and Janeway later demonstrated that 
a homologous receptor (later identified as TLR4) exists in 
higher organisms including humans [2]. As many as eleven 
human and thirteen murine TLRs have subsequently been 
identified to date. 
  These receptors each contain a ligand binding domain 
with multiple leucine rich repeats, a transmembrane domain, 
and a Toll/IL-1R (TIR) signaling domain [3-5]. While they 
are similar in structure, TLRs differ both in their subcellular 
localization as well as the ligands that they recognize. For 
example, TLR1, -2, -4, -5, and -6 are predominantly located 
at the cell surface while TLR3, -7, and -9 are generally 
localized to the endosomal compartment in most inflamma-
tory cell types. TLRs serve as pattern recognition receptors 
by sensing the presence of conserved microbial motifs and 
alerting the host to the presence of microbial invaders. 
TLR1, -2, and -6 detect microbial lipopeptides. TLR4, in 
conjunction with CD14 and MD2, senses the presence of 
lipopolysaccharide (LPS). Flagellin is the ligand of TLR5.  
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TLR3 and -7 detect double stranded RNA and single stran-
ded RNA, respectively, while TLR9 alerts the host to the 
presence of bacterial CpG DNA [6] and perhaps endogenous 
DNA motifs [7]. 
  Upon TLR stimulation by corresponding ligands, intra-
cellular adaptor proteins are recruited to the signaling com-
plex and mediate downstream signaling [8,9]. Most TLRs, 
with the exception of TLR3, utilize the intracellular adaptor 
myeloid differentiation factor 88 (MyD88). After MyD88 is 
recruited to the signaling complex, downstream pathways are 
activated, culminating in the activation of nuclear factor-B
(NF-kB) [10]. TLR3 stimulation leads to recruitment of an 
adaptor known as TIR domain-containing-adaptor inducing 
IFN (TRIF) [11,12]. Through a number of downstream 
mediators, TRIF goes on to activate IRF3 and IRF7 and 
result in the production of Type I interferons. Interestingly, 
TLR4 can utilize both MyD88 and TRIF as adaptors for 
signaling (Fig. 1). While these pathways are conceptually 
thought of as distinct, it should be noted that there is overlap 
between the two. TRIF-dependent signaling can result in 
activation of NF-kB [13,14] and conversely MyD88-
dependent signaling can result in IRF activation [15]. 
  TLR4 is one of the most thoroughly studied members of 
the TLR family. TLR4 was initially identified as the 
molecular sensor for bacterial LPS when Poltorak, Beutler, 
and colleagues demonstrated that the failure of C3H/HeJ and 
C57Bl/10ScCr mice to respond to LPS is due to mutations in 
the tlr4 gene [16]. A number of other studies have also found 
that TLR4 can sense the presence of a number of 
endogenous molecules which can be released from damaged 
or ischemic tissues. Heparan sulfate, hyaluronan, fibrinogen, 
high mobility group box-1 (HMGB1) and others have been 
implicated as endogenous activators of TLR4 signaling [17-
24]. Accordingly, TLR4 has been identified as a mediator of 
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tissue injury including hemorrhagic shock [25,26] and femur 
fracture [27] as well as hepatic [28-31], renal [32], and 
pulmonary [33] warm I/R injury.  
TLRS AND MYOCARDIAL DYSFUNCTION IN 
SEPSIS 
  Sepsis can result in pronounced myocardial dysfunction, 
characterized by contractile impairment of cardiomyocytes. 
Further, cardiomyocytes can adopt a pro-inflammatory 
phenotype, marked by production of pro-inflammatory 
cytokines and expression of adhesion molecules. Recent 
evidence implicates TLRs as mediators of myocardial 
dysfunction in the setting of sepsis. 
  Boyd and colleagues demonstrated that multiple TLRs, 
including TRL2, -3, -4, -5, -7, and -9 are expressed in murine 
heart tissue and a murine cardiomyocyte cell line [34]. The 
authors found that stimulation with ligands for TLR2, -4, or -
5 results in impaired contraction of primary murine ventri-
cular myocytes through a NF-B-dependent mechanism. In 
addition, interleukin-6 (IL-6), keratinocyte-derived cytokine 
(KC), macrophage inflammatory protein-2 (MIP2) produc-
tion and increased intercellular adhesion molecule-1 (ICAM-
1) expression was observed after stimulation of a cardio-
myocyte cell line with TLR ligands, particularly LPS. This 
also occurred in a NF-B-dependent manner. The results of 
this study suggest that the cardiomyocyte itself is able to 
sense the presence of PAMPs through TLRs, and adopt a 
pro-inflammatory phenotype in response. Furthermore, this 
data argues that the contractile function of the cardiomyocyte 
can be directly modulated through TLR stimulation. 
  In a separate study, Baumgarten and co-investigators 
found that stimulation of ventricular myocytes with LPS 
resulted in reduced sarcomere shortening amplitude and 
prolonged duration of relaxation [35]. In contrast, contractile 
function was not impaired in cardiomyocytes from TLR4-
mutant mice after stimulation with LPS. A soluble inhibitor 
of TLR4 was also able to prevent contractile dysfunction in 
wild-type cells. In accordance with the findings of Boyd and 
colleagues, these results suggest that stimulation of TLR4 on 
cardiomyocytes leads directly to contractile dysfunction.  
  Tavener and colleagues also observed that mice expe-
rienced cardiac dysfunction after LPS injection [36]. 
However, they found that chimeric mice with TLR4-mutant 
leukocytes and TLR4 wild-type cardiomyocytes had no 
myocardial impairment in response to LPS, while mice with 
TLR4 wild-type leukocytes and TLR4 deficient cardiomyo-
cytes demonstrated reduced myocyte shortening in response 
to LPS. These observations differ from those of Boyd [34] 
and Baumgarten [35], as they argue that TLR4 on immune 
cells, rather than cardiomyocytes, is responsible for 
myocardial impairment in response to LPS. Technical factors 
may be in part responsible for the different conclusions from 
these studies. Also, there may be a role for both myocardial 
and immune cell TLR4 signaling in cardiac dysfunction in 
response to LPS. However, additional study will be required 
Fig. (1). TLR4 Signaling. In conjunction with CD14 and MD2, TLR4 senses the presence of bacterial LPS and alerts the immune system to 
the presence of bacterial invaders. It has also been demonstrated that TLR4 can sense the presence of endogenous molecules that are released 
from damaged or ischemic tissues and initiate an inflammatory response. The roles of CD14 and MD2 in the detection of endogenous
molecules are less clear. The molecular details of TLR4 signaling have not yet been entirely defined, but upon activation, it is likely that 
TLR4 clustering occurs. Intracellular adaptor proteins are then recruited and the signal is transmitted inside the cell, ultimately resulting in 
activation of the cell and a robust inflammatory response. TLR4 signaling through MyD88 ultimately results in NF-kB activation and release 
of pro-inflammatory cytokines while TLR4 signaling through the adaptor TRIF results in IRF activation and Induction of type I interferons. 
Some overlap may occur between these two pathways, as indicated here by dashed, gray arrows. 198 Current Cardiology Reviews, 2009, Vol. 5, No. 3 Kaczorowski et al. 
to further clarify the mechanisms of TLR4-mediated 
myocardial dysfunction in sepsis 
TLR4 IN MYOCARDIAL WARM I/R 
Warm myocardial I/R injury is encountered in settings 
including cardiac ischemia and subsequent restoration of 
blood flow with directed percutaneous interventions. Several 
investigators have explored the role of TLR4 in warm 
myocardial I/R. The results of multiple studies reveal that 
myocardial injury and associated inflammation is reduced in 
the absence of TLR4 signaling (Table 1). 
Using a temporary left anterior descending (LAD) artery 
occlusion model, Oyama and colleagues first observed 
reduced myocardial infarct size in 2 distinct strains of mice 
that lack functional TLR4 signaling [37]. Further, compared 
to those from wild-type animals, the authors observed 
reduced neutrophil infiltration as measured both by 
immunohistochemical staining and myeloperoxidase (MPO) 
activity in TLR4-deficient hearts. Accordingly, fewer lipid 
peroxidation products were measured in TLR4-deficient 
hearts after I/R. There was also less complement deposition 
in hearts from TLR4-deficient mice compared to controls 
after I/R, suggesting that TLR4 signaling might somehow 
influence local synthesis, activation, or deposition of 
complement. 
  These results were confirmed by Chong and co-
investigators, who also utilized a similar regional warm 
myocardial I/R model to demonstrate that TLR4 is a 
mediator of myocardial injury and inflammation after I/R 
[38]. After I/R, Chong and colleagues found that TLR4 
mutant mice exhibited significantly smaller infarcts. These 
investigators also found reduced activation of c-Jun N 
terminal kinase (JNK) and significantly lower transcript 
levels of a number of a number of pro-inflammatory 
cytokines, including IL-1, IL-6, and monocyte chemotactic 
protein-1 (MCP-1).  
  Furthermore, the phosphatidylinositol-3 kinase (PI3K) 
pathway may be partially responsible for the observed 
reduction in myocardial injury after warm I/R [39]. 
Pretreatment of animals with pharmacologic inhibitors of the 
PI3K/Akt signaling pathway, including either wortmannin or 
Ly294002, abrogated the observed reduction of myocardial 
infarct (MI) size in TLR4 deficient animals. Inhibition of the 
PI3/Akt pathway also increased apoptosis of cardiomyocytes 
after I/R. These effects appear to be independent of NF-B,
but increased phosphorylation of myocardial phosphatase 
and tensin homolog deleted on chromosome 10 (PTEN) and 
glycogen synthase kinase-3 may play a role.  
Collectively, these studies implicate TLR4 as a mediator 
of myocardial injury and inflammation after warm I/R. In 
each of these studies, animals with either a mutation in the 
signaling domain of the tlr4 gene or lacking the gene 
encoding TLR4 altogether were used to study the role of 
TLR4 warm I/R of the heart. In order to evaluate the clinical 
potential of TLR4 inhibition in myocardial warm I/R, 
Shimamoto and co-investigators employed a compound 
Table 1. TLR4 as a Mediator of Myocardial Ischemia/Reperfusion Injury
Study  Year  Model  Technique  TLR4  Findings 
Oyama et al.
[37] 
2004 Warm 
ischemia 
Temporary LAD occlusion; 1 
hr ischemia, 24 hrs reperfusion 
Genetic deficiency of 
TLR4 
Reduced infarct size, inflammatory infiltrate, lipid 
peroxidation, and complement deposition in the 
absence of TLR4 signaling 
Chong et al.
[38] 
2004 Warm 
ischemia 
Temporary LAD occlusion; 1 
hr ischemia, up to 2 hrs 
reperfusion 
Genetic deficiency of 
TLR4 
Reduced infarct size, MAP kinase activation, pro-
inflammatory cytokine mRNA production in mice 
deficient in TLR4 signaling 
Hua et al. [41]  2005  Warm 
ischemia 
Temporary LAD occlusion; 45 
min ischemia, 4 hrs 
reperfusion 
Inhibition of MyD88 
using dominant negative 
genetic construct 
Reduced infarct size, NF-B activation, 
cardiomyocyte apoptosis, increased Akt 
phosphorylation and BCL-2 expression after 
inhibition of MyD88 signaling 
Shimamoto  
et al. [40]  2006 Warm 
ischemia 
Temporary LAD occlusion; 30 
min ischemia, upto 2 hrs 
reperfusion 
Blockade of TLR4 
signaling with a soluble 
inhibitor 
Reduced infarct size, MAP kinase activation, NF-
B activation, pro-inflammatory cytokine mRNA 
production after inhibition of TLR4 with a soluble 
inhibitor, Eritoran 
Hua et al. [39]  2007  Warm 
ischemia 
Temporary LAD occlusion;  
45 min ischemia, 4 hrs 
reperfusion 
Genetic deficiency of 
TLR4, 
Pharmacologic inhibition 
of PI3/Akt signaling 
Pharmacologic inhibition of PI3K/Akt signaling 
abrogates the reduction of myocardial injury 
observed in the absence of TLR4 signaling 
Kaczorowski 
et al. [42] 
2007 Cold 
ischemia 
Global ischemia in cold 
preservation solution followed 
by heterotopic transplantation; 
2 hrs cold ischemia, 3 or 24 
hrs reperfusion 
Genetic deficiency of 
TLR4 
Reduced systemic and intragraft inflammatory 
mediators, reduced NF-B activation, and reduced 
myocardial injury as measured by serum troponins 
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known as Eritoran, a soluble analog of lipid A that serves as 
an inhibitor of TLR4 [40]. The authors found that 
pretreatment of animals with Eritoran significantly reduced 
infarct size in a murine model of regional myocardial I/R. 
Less phosphorylation of JNK and less NF-B nuclear 
translocation was observed in hearts of animals that were 
pre-treated with Eritoran compared to those from control 
animals. 
To better understand whether the intracellular adaptor 
MyD88 plays a role in TLR4-mediated myocardial I/R 
injury, Hua and colleagues transfected the myocardium of 
rats with an adenoviral construct containing a dominant 
negative MyD88 gene, which served to block MyD88 
signaling. Inhibition of MyD88 signaling with the dominant 
negative MyD88 construct prevented NF-B activation, 
stimulated PI3K/Akt pathway, and ultimately protected the 
myocardium from injury after I/R compared to controls [41]. 
These observations suggest that the MyD88-dependent 
pathway plays a role in warm I/R injury, but these findings 
do not exclude a role for the adaptor TRIF as a potential 
mediator of inflammation and organ injury after I/R. 
TLR4 IN MYOCARDIAL COLD I/R 
  In the process of solid organ transplantation, whole 
organs are flushed and stored in cold preservation solution 
and then subsequently re-implanted and reperfused with 
warm blood. I/R injury in solid organ transplantation is of 
particular interest, as it can affect graft function and may 
impact upon patient survival as well.  
  Our group sought to determine whether TLR4 mediates 
the early inflammatory response and organ injury in a model 
of cold I/R. In order to address this question, we performed 
heterotopic cardiac transplants in both wild-type mice and 
mice deficient in TLR4 signaling due to a point mutation 
[42]. In wild-type mice, we observed significant elevations 
in the serum levels of a number of pro-inflammatory 
cytokines, particularly IL-6 and the chemotactic factor MCP-
1. Tumor necrosis factor  (TNF) and IL-1 levels were 
also elevated, but to a substantially lesser extent. Interes-
tingly, lower systemic levels of each of these cytokines were 
observed in TLR4 mutant mice. Further, we utilized 
quantitative reverse transcriptase-polymerase chain reaction 
(RT-PCR) to measure a number of intra-graft inflammatory 
mediators and found that there was also significantly less 
upregulation of TNF, IL-6, IL-1, and ICAM-1 mRNA in 
TLR4 mutant mice compared to controls. These data 
demonstrated that TLR4 mediates both systemic and intra-
graft inflammation in the after cold I/R in the setting of an 
experimental model of cardiac transplantation. We also 
observed significantly lower levels of serum troponin I in 
TLR4 mutant mice compared to wild-type controls  
   TLR4 is expressed on multiple different donor and reci-
pient cell types including leukocytes, endothelial cells, 
dendritic cells, and cardiomyocytes. In order to determine 
whether TLR4 signaling on donor or recipient cells contri-
butes to the early inflammatory response in the setting of 
cold I/R, we performed transplants using TLR4 mutant mice 
as donors with TLR4 wild-type mice as recipients. In 
addition, we also performed transplants using TLR4 wild-
type mice as donors with TLR4 mutant mice as recipients.  
Interestingly, if TLR4 signaling was absent in either donor or 
recipient cells, the observed inflammatory response was 
reduced. Our data implicate TLR4 as a key mediator of 
inflammation and myocardial injury after I/R and further 
suggest that TLR4 signaling on both graft and recipient cells 
contributes to systemic and intragraft inflammatory 
responses in the setting of cold I/R. Further study will be 
required to better understand the nature of the ligands that 
stimulate TLR4 in the setting of cold I/R injury. The 
intracellular pathways utilized by TLR4 to mediate 
inflammation and organ injury after cold I/R will also 
require further study. 
TLR4 AND ATHEROSCLEROSIS 
  Evidence is also accumulating for a potential role for 
TLRs, particularly TLR4, in the development of atheroscle-
rosis. A possible role for TLR4 in atherogenesis was 
suggested when Xu and co-investigators made the observa-
tion that TLR4 is expression is abundant in both murine and 
human atherosclerotic plaques and that TLR4 appears to be 
upregulated in response to oxidized low-density lipoprotein 
[43]. It was subsequently demonstrated that genetic defi-
ciency of either TLR4 or the adaptor MyD88 results in 
reduced development of plaque in atherosclerotic prone 
Apoe-/- mice despite persistent hypercholersterolemia [44]. 
Others have also observed that MyD88 plays a key role in 
murine models of atherosclerosis [45]. In another study, 
overexpression of TLR2 and TLR4 in the carotid arterial 
vessel wall in a rabbit model led to accelerated 
atherosclerosis in animals fed a high fat diet [46]. 
The results of these small animal studies have been 
supported by population studies examining the develop- 
ment of atherosclerosis in humans with polymorphisms 
(Asp299Gly and Thr399Ile) in TLR4, which impair its 
ability to elicit an inflammatory response[47]. Kiechl and co-
investigators found that 55 out of 810 subjects carried the 
Asp299Gly TLR4 allele. Compared to those with wild-type 
TLR4, those carrying the Asp299Gly allele had lower levels 
of circulating inflammatory mediators and were more 
predisposed to severe bacterial infections, but had a lower 
risk of carotid atherosclerosis [48]. In a smaller case control 
study, Ameziane and colleagues found that the Asp299Gly 
allele was associated with decreased risk of acute coronary 
events, as well as a decrease in plasma fibrinogen and 
soluble ICAM-1 [49]. The Asp299Gly variant was also 
found to be associated with a lower risk of myocardial 
infarction [50] and other cardiovascular events [51] in 
patients receiving statins. Despite these findings, the results 
of multiple other studies have failed to demonstrate a 
consistent relationship between TLR4 polymorphisms and 
the development of atherosclerotic disease [52-59]. Based on 
these conflicting results, further careful evaluation of the role 
of TLR4 in atherosclerosis is warranted. 
TLR4 IN MALADAPTIVE VENTRICULAR 
REMODELING 
  Chronic ventricular remodeling after an ischemic insult 
can lead to the eventual development of congestive heart 
failure. Several well known factors, including -adrenergic 
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sterone system, contribute to the development of maladap-
tive remodeling after myocardial infarction. Inflammatory 
responses to necrotic tissue and matrix turnover are 
processes that also contribute to this process. Using a murine 
model involving permanent coronary ligation in wild-type 
and TLR4-mutant mice, Timmers and colleagues inves-
tigated whether TLR4 is involved in ventricular remodeling 
after myocardial infarction [60]. They demonstrated that 
mice deficient in TLR4 signaling exhibited reduced 
inflammation, as measured by macrophage infiltration and 
expression of pro-inflammatory cytokines, in the infarcted 
area. There was also significantly less matrix metallopro-
teinase-2 and -9 activity in the hearts of mutant mice. In the 
non-infarcted areas, there was less interstitial fibrosis and 
myocardial hypertrophy in the hearts of TLR4 mutant 
animals compared to those form wild-type animals. 
Furthermore, after infarction, hearts from TLR4-mutant 
animals demonstrated less change in ventricular end-
diastolic volume and also exhibited preserved systolic 
function.  
  The results of a number of other studies suggest that 
TLR4 plays an important role in maladaptive ventricular 
remodeling after ischemic injury or that TLR4 signaling is 
altered in the setting of heart failure. Increased TLR4 
expression has been observed in murine hearts after ischemic 
injury and in human heart tissue from patients with 
idiopathic dilated cardiomyopathy [61]. Others have found 
that surface TLR4 expression levels are higher in monocytes 
from patients that have suffered a recent acute myocardial 
and that these cells produce greater amounts of cytokines 
compared to those from health human controls [62]. Further, 
monocytes from patients that went on to develop heart 
failure after suffering an MI had higher levels of TLR4 
surface expression and produced greater amounts of 
cytokines, including IL-6, TNF, and granulocyte/macro-
phage-colony stimulating factor (GM-CSF), upon LPS 
stimulation compared to those from patients who did not 
develop heart failure after MI.  
  Based on the observation that NF-B activation can lead 
to cardiomyocyte hypertrophy and that TLR4 stimulation 
can result in NF-B activation, Ha and co-investigators 
hypothesized that TLR4 signaling might play a role in 
cardiomyocyte hypertrophy in an in vivo model [63]. In 
order to test their hypothesis, the authors employed a model 
involving aortic banding to induce pressure overload. 
Interestingly, significantly less myocardial hypertrophy and 
less NF-B activation was observed in TLR4 deficient mice 
compared to wild-type controls. Another recent study has 
also demonstrated that improved ventricular function and 
less oxidative stress, inflammation, and apoptosis in TLR4 
deficient mice compared to wild-type controls in the setting 
of doxorubicin-induced cardiomyopathy in mice [64]. 
Collectively, these findings suggest that TLR4 not only plays 
a role in adverse ventricular remodeling after ischemic 
injury, but that TLR4 also mediates maladaptive responses in 
response to other stimuli as well. 
CONCLUSIONS 
  In summary, the etiology of myocardial I/R injury is 
multifactorial, but activation of the innate immune system  
and the resultant inflammatory response are important 
components of I/R injury. Toll-like receptor 4 (TLR4), 
which was initially identified as the sensor for bacterial 
lipopolysaccharide (LPS), has also been shown to serve as a 
sensor for endogenous molecules released from damaged or 
ischemic tissues. The studies reviewed here demonstrate that 
TLR4 not only plays a role as a mediator of cardiac 
dysfunction in sepsis, but also serves as a key mediator of 
myocardial injury and inflammation in the setting of I/R. In 
addition, TLR4 signaling contributes to the maladaptive 
ventricular remodeling that may occur after ischemic 
myocardial injury. Further study will be required to identify 
the ligands that stimulate TLR4 in the setting of myocardial 
I/R injury and to better understand intracellular pathways 
that mediate TLR4 signaling after I/R. A better unders-
tanding of these pathways may lead to the development of 
therapeutic strategies to mitigate myocardial I/R injury. 
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